论文部分内容阅读
最近,由美国肝脏病研究协会(AASLD)主办的官方杂志《肝脏病学》刊文指出,他汀类药物对脂肪肝病患者来说似乎是安全的,且患者可获益于其降胆固醇的能力。他汀类药物通过抑制肝脏的胆固醇生成来降低胆固醇水平;此前研究已证实他汀类药物可降低动脉粥样硬化与相关疾病的风险。但通常情况下,使用他汀类药物的患者的肝酶水平升高。现有的他汀类产品包装上建议在使用期间对患者的肝值进行监测。该建议提示医生应加以关注,让患者了解自己的肝脏情况,包括无症状的肝酶升高。
Recently, an article in the journal “Hepatology”, an official magazine sponsored by the American Association for the Study of Liver, pointed out that statins appear to be safe for patients with fatty liver and that patients can benefit from their cholesterol-lowering ability. Statins lower cholesterol levels by inhibiting liver cholesterol production; previous studies have shown that statins reduce the risk of atherosclerosis and related diseases. However, in general, patients with statins have elevated levels of liver enzymes. The current statin package is recommended for monitoring the patient’s liver value during use. This advice prompts the doctor to pay attention and let the patient know about his liver, including asymptomatic liver enzymes.